RAS mutation

News alerts, weekly reports and conference planners

RAS mutation	Thyroid Gland Medullary Carcinoma	RAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
RAS mutation	Acute Myelogenous Leukemia	RAS mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
RAS mutation	Multiple Myeloma	RAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
RAS mutation	Thyroid Gland Anaplastic Carcinoma	RAS mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3
RAS mutation	Thyroid Gland Carcinoma	RAS mutation	Thyroid Gland Carcinoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3
RAS mutation	Rectal Cancer	RAS mutation	Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials SOXIRI Sensitive : C3	SOXIRI Sensitive: C3 – Early Trials SOXIRI Sensitive : C3
RAS mutation	Rectal Cancer	RAS mutation	Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials FOLFOXIRI Sensitive : C3	FOLFOXIRI Sensitive: C3 – Early Trials FOLFOXIRI Sensitive : C3
RAS mutation	Acute Myelogenous Leukemia	RAS mutation	Acute Myelogenous Leukemia	mTOR inhibitor Resistant: D – Preclinical mTOR inhibitor Resistant : D	mTOR inhibitor Resistant: D – Preclinical mTOR inhibitor Resistant : D
RAS mutation	Rhabdomyosarcoma	RAS mutation	Rhabdomyosarcoma	trametinib + AMG 479 Sensitive: D – Preclinical trametinib + AMG 479 Sensitive : D	trametinib + AMG 479 Sensitive: D – Preclinical trametinib + AMG 479 Sensitive : D
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	IMM-6-415 Sensitive: D – Preclinical IMM-6-415 Sensitive : D	IMM-6-415 Sensitive: D – Preclinical IMM-6-415 Sensitive : D
RAS mutation	Pancreatic Ductal Adenocarcinoma	RAS mutation	Pancreatic Ductal Adenocarcinoma	IMM-6-415 Sensitive: D – Preclinical IMM-6-415 Sensitive : D	IMM-6-415 Sensitive: D – Preclinical IMM-6-415 Sensitive : D

RAS mutation

Associations